NZ598618A - Pharmaceutical combination for treating tumor - Google Patents

Pharmaceutical combination for treating tumor

Info

Publication number
NZ598618A
NZ598618A NZ598618A NZ59861810A NZ598618A NZ 598618 A NZ598618 A NZ 598618A NZ 598618 A NZ598618 A NZ 598618A NZ 59861810 A NZ59861810 A NZ 59861810A NZ 598618 A NZ598618 A NZ 598618A
Authority
NZ
New Zealand
Prior art keywords
antisense
antibody
fatty acid
effective amount
formula
Prior art date
Application number
NZ598618A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NZ598618A publication Critical patent/NZ598618A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ598618A 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor NZ598618A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24301909P 2009-09-16 2009-09-16
PCT/JP2010/066619 WO2011034210A1 (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Publications (1)

Publication Number Publication Date
NZ598618A true NZ598618A (en) 2014-10-31

Family

ID=43730802

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598618A NZ598618A (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Country Status (17)

Country Link
US (3) US9084815B2 (https=)
EP (1) EP2477632A4 (https=)
JP (2) JP5891168B2 (https=)
KR (1) KR101760963B1 (https=)
CN (2) CN107050458A (https=)
AR (1) AR078182A1 (https=)
AU (1) AU2010296307B2 (https=)
BR (1) BR112012005896A2 (https=)
CA (1) CA2772314A1 (https=)
IL (1) IL218392A (https=)
MX (1) MX2012003188A (https=)
NZ (1) NZ598618A (https=)
RU (2) RU2577700C2 (https=)
SG (2) SG179153A1 (https=)
TW (1) TWI535436B (https=)
WO (1) WO2011034210A1 (https=)
ZA (1) ZA201201894B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
DK0454429T3 (da) 1990-04-27 1997-03-17 R Tech Ueno Ltd Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
RU2071780C1 (ru) * 1993-10-11 1997-01-20 Научно-производственное предприятие "Фармэк" Способ лечения медикаментозных эзофаго-гингиво-стоматитов
JPH0770054A (ja) 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3187438B2 (ja) * 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
EP1267882B1 (en) 2000-03-24 2009-04-15 Sucampo AG Prostaglandins for the treatment of eye disease caused by light irradiation like photoretinitis
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
DK1841433T3 (da) 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound

Also Published As

Publication number Publication date
RU2016103415A (ru) 2018-11-22
WO2011034210A1 (en) 2011-03-24
ZA201201894B (en) 2012-11-28
RU2577700C2 (ru) 2016-03-20
CA2772314A1 (en) 2011-03-24
US20110064748A1 (en) 2011-03-17
AU2010296307A1 (en) 2012-04-05
AU2010296307B2 (en) 2016-02-11
US20150272961A1 (en) 2015-10-01
EP2477632A1 (en) 2012-07-25
TW201116277A (en) 2011-05-16
RU2012114771A (ru) 2013-10-27
EP2477632A4 (en) 2013-06-12
JP2016056191A (ja) 2016-04-21
SG179153A1 (en) 2012-04-27
BR112012005896A2 (pt) 2016-03-15
KR101760963B1 (ko) 2017-07-24
IL218392A (en) 2016-05-31
TWI535436B (zh) 2016-06-01
JP2013504520A (ja) 2013-02-07
MX2012003188A (es) 2012-04-30
IL218392A0 (en) 2012-04-30
CN107050458A (zh) 2017-08-18
KR20120081139A (ko) 2012-07-18
US9084815B2 (en) 2015-07-21
AR078182A1 (es) 2011-10-19
SG10201405467PA (en) 2014-10-30
CN102481302A (zh) 2012-05-30
JP5891168B2 (ja) 2016-03-22
US20170079986A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
HRP20220399T1 (hr) Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
HRP20180104T1 (hr) Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3
Nguyen et al. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis
MX2013011327A (es) Combinaciones de compuestos inhibidores de akta y agentes quimioterapeuticos y metodos de uso de los mismos.
AU2012229062A1 (en) Overcoming resistance to ErbB pathway inhibitors
Wang et al. Exposure–response relationship of T‐DM1: insight into dose optimization for patients with HER2‐positive metastatic breast cancer
NZ610851A (en) Compounds and compositions for the treatment of cancer
RU2009132674A (ru) Комбинированная терапия с использованием ингибиторов ангиогенеза
JP2014034576A5 (https=)
HRP20161114T1 (hr) Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama
JP2015532292A5 (https=)
EA201270730A1 (ru) ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ
CR20120528A (es) Métodos para tratar el cáncer
TW200519104A (en) Quinazoline derivatives
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP2018534289A5 (https=)
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
JP2013520431A5 (https=)
NZ598618A (en) Pharmaceutical combination for treating tumor
EP2501385A1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
Gatti et al. Drug combinations with proteasome inhibitors in antitumor therapy
Satolli et al. Gastric cancer: The times they are a-changin’
RU2016147521A (ru) Способы применения антител к ang2
JP2017514854A5 (https=)
MX2013014071A (es) Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 SEP 2017 BY HENRY HUGHES IP LIMITED

Effective date: 20150430

LAPS Patent lapsed